Quinupristin/dalfopristin

Uses

Antibiotic: treatment of vancomycin-resistant Enterococcus faecium, as well as nosocomial pneumonias and infections secondary to IV catheters (1)

Pregnancy Rating: B
Lactation risk: unknown whether secreted in human breast milk. Caution should be exercised when administering to nursing mothers. (2)

dosage may need to be adjusted in patients with cirrhosis, however specific dose modification is not known at this time (2)

Group	Organism	Sensitivity
Gram Positive	Strep. Group A, B, C, G	S
	Strep. Pneumoniae	S
	Viridans strep	X1
	Strep. anginosus gp	X1
	Enterococcus faecalis	R
	Enterococcus faecium	S
	MSSA	S
	MRSA	S
	CA-MRSA	S
	Staph. Epidermidis	S
	C. jeikeium	S
	L. monocytogenes	S
Gram Negatives	N. gonorrhoeae	X2
	N. meningitidis	R
	Moraxella catarrhalis	S
	H. influenzae	I
	E. coli	R
	Klebsiella sp	R
	E. coli/Klebsiella ESBL+	R
	E coli/Klebsiella KPC+	R
	Enterobacter sp, AmpC neg	R
	Enterobacter sp, AmpC pos	R
	Serratia sp	X1
	Serratia marcescens	X1
	Salmonella sp	R
	Shigella sp	R
	Proteus mirabilis	X1
	Proteus vulgaris	X1
	Providencia sp.	X1
	Morganella sp.	X1
	Citrobacter freundii	X1
	Citrobacter diversus	X1
	Citrobacter sp.	X1
	Aeromonas sp	X1
	Acinetobacter sp.	X1
	Pseudomonas aeruginosa	R
	Burkholderia cepacia	X1
	Stenotrophomonas maltophilia	X1
	Yersinia enterocolitica	X1
	Francisella tularensis	X1
	Brucella sp.	X1
	Legionella sp.	X1
	Pasteurella multocida	X1
	Haemophilus ducreyi	X1
	Vibrio vulnificus	X1
Misc	Chlamydophila sp	X2
	Mycoplasm pneumoniae	S
	Rickettsia sp	X1
	Mycobacterium avium	R
Anaerobes	Actinomyces	X1
	Bacteroides fragilis	X1
	Prevotella melaninogenica	S
	Clostridium difficile	I
	Clostridium (not difficile)	X2
	Fusobacterium necrophorum	X1
	Peptostreptococcus sp.	X1

S susceptible/sensitive (usually)
I intermediate (variably susceptible/resistant)
R resistant (or not effective clinically)
S+ synergistic with cell wall antibiotics
U sensitive for UTI only (non systemic infection)
X1 no data
X2 active in vitro, but not used clinically
X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
X4 active in vitro, but not clinically effective for strep pneumonia

1. JP Manzanella. "Quinupristin-Dalfopristin: A New Antibiotic for Severe Gram-Positive Infections." American Family Physician. 2001 Dec 1;64(11):1863-1867.
2. U.S. Food and Drug Administration. Synercid I.V. November 2007. Retrieved from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050748s008,050747s008lbl.pdf

This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.